# Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

> **NCT00002238** · PHASE3 · COMPLETED · sponsor: **Bayer**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Interferon beta-1b
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002238
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002238, "Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00002238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*